AR075873A1 - Reconstitucion in situ de una vacuna para la administracion a un grupo de animales predeterminado - Google Patents

Reconstitucion in situ de una vacuna para la administracion a un grupo de animales predeterminado

Info

Publication number
AR075873A1
AR075873A1 ARP100100856A ARP100100856A AR075873A1 AR 075873 A1 AR075873 A1 AR 075873A1 AR P100100856 A ARP100100856 A AR P100100856A AR P100100856 A ARP100100856 A AR P100100856A AR 075873 A1 AR075873 A1 AR 075873A1
Authority
AR
Argentina
Prior art keywords
vaccine
animals
situ
administration
reconstitution
Prior art date
Application number
ARP100100856A
Other languages
English (en)
Inventor
Alexander Albertus Stephanus Eggen
Stefano Gozio
Original Assignee
Intervet Int Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intervet Int Bv filed Critical Intervet Int Bv
Publication of AR075873A1 publication Critical patent/AR075873A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Medicinal Preparation (AREA)
  • Surgical Instruments (AREA)

Abstract

Método para reconstituir una vacuna para la administracion a un grupo de animales predeterminado que comprende proveer un conjunto de multiples antígenos inactivados, estando presente cada antígeno inactivado en una forma liofilizada y envasado en un recipiente, proveer un vehículo líquido que es farmacéuticamente aceptable para los animales, determinar los riesgos para la salud con relacion a infecciones microbianas para este grupo de animales, establecer cuales de los uno o más antígenos inactivados en dicho conjunto corresponde a estos riesgos para la salud, tomar uno o más de los recipientes correspondientes a los uno o más antígenos inactivados y mezclar el contenido liofilizado de dichos uno o más recipientes con el vehículo para preparar la vacuna. Método para producir multiples antígenos inactivados distintos para reconstituir la vacuna, a un kit de partes y a un método para permitir la reconstitucion in situ de la vacuna. Reivindicacion 5: Un método de acuerdo con cualquiera de las reivindicaciones precedentes, caracterizado porque la forma liofilizada comprende una o más liosferas.
ARP100100856A 2009-03-19 2010-03-18 Reconstitucion in situ de una vacuna para la administracion a un grupo de animales predeterminado AR075873A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16162609P 2009-03-19 2009-03-19
EP09155612 2009-03-19

Publications (1)

Publication Number Publication Date
AR075873A1 true AR075873A1 (es) 2011-05-04

Family

ID=40875190

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100100856A AR075873A1 (es) 2009-03-19 2010-03-18 Reconstitucion in situ de una vacuna para la administracion a un grupo de animales predeterminado

Country Status (9)

Country Link
US (1) US20120328667A1 (es)
EP (1) EP2408430A1 (es)
JP (1) JP2012520849A (es)
CN (1) CN102341097A (es)
AR (1) AR075873A1 (es)
BR (1) BRPI1009408A2 (es)
TW (1) TW201043267A (es)
UY (1) UY32498A (es)
WO (1) WO2010106095A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10130699B2 (en) * 2013-12-03 2018-11-20 Intervet Inc. Vaccine against Lawsonia intracellularis and porcine circovirus 2
WO2019076864A1 (en) 2017-10-17 2019-04-25 Intervet International B.V. RECOMBINANT EXPRESSION OF PCV2B ORF2 PROTEIN IN INSECT CELLS

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5452794A (en) * 1977-09-30 1979-04-25 Kousaku Yoshida Extracting of polysacchride from capusle containing epidermis staphylococus
JPS5459316A (en) * 1977-10-18 1979-05-12 Takeda Chem Ind Ltd Preparation of stable, freeze-dried vaccine for japanese encephalitis
JPS6013718A (ja) * 1983-07-05 1985-01-24 Chemo Sero Therapeut Res Inst Ｂ型肝炎ワクチン
JPS60193925A (ja) * 1984-03-13 1985-10-02 Chemo Sero Therapeut Res Inst 凍結乾燥製剤化ワクチン
JPH0761955B2 (ja) * 1988-04-28 1995-07-05 国立予防衛生研究所長 凍結乾燥ａ型肝炎ワクチン
CA2222455C (en) * 1995-03-22 2013-05-28 Smithkline Beecham Biologicals S.A. A vaccine composition comprising a polysaccharide conjugate antigen adsorbed onto aluminium phosphate
IL120202A (en) * 1996-03-07 2001-03-19 Akzo Nobel Nv Container with freeze-dried vaccine components
JPH09248177A (ja) 1996-03-18 1997-09-22 Snow Brand Milk Prod Co Ltd 乾燥微生物菌体の製造法
JP2001502935A (ja) 1996-09-26 2001-03-06 アクゾ・ノベル・エヌ・ベー 針無し注射器
IL140769A0 (en) * 1998-07-14 2002-02-10 Upjohn Co Oxazolidinones to treat eye infections
PT1140152E (pt) * 1998-12-21 2003-11-28 Akzo Nobel Nv Metodo para producao de vacinas inactivadas adjuvadas com uma emulsao a/o
AU2003245919A1 (en) 2002-06-10 2003-12-22 Akzo Nobel N.V. Needle-less injector
WO2006008006A1 (en) * 2004-07-23 2006-01-26 Bayer Technology Services Gmbh Sterile freezing, drying, storing, assaying and filling process (sfd-saf process) (pellet freeze-drying process for parenteral biopharmaceuticals)
MX2007003726A (es) * 2004-09-28 2007-06-15 Johnson & Johnson Estabilizaci??n de agentes inmunologicamente activos con adyuvantes de alumbre.
TWI398272B (zh) * 2005-03-08 2013-06-11 Intervet Int Bv 化學定義的安定劑
CN101095950B (zh) * 2006-06-30 2011-01-26 辽宁成大生物股份有限公司 一种稳定的人用狂犬病疫苗冻干制剂及其制备

Also Published As

Publication number Publication date
BRPI1009408A2 (pt) 2016-03-01
US20120328667A1 (en) 2012-12-27
CN102341097A (zh) 2012-02-01
EP2408430A1 (en) 2012-01-25
JP2012520849A (ja) 2012-09-10
UY32498A (es) 2010-10-29
TW201043267A (en) 2010-12-16
WO2010106095A1 (en) 2010-09-23

Similar Documents

Publication Publication Date Title
AR124676A2 (es) Formulación farmacéutica que comprende una droga biofarmacéutica
ITUA20163461A1 (it) Una capsula, un sistema per preparare una bevanda potabile da tale capsula e uso di tale capsula in un dispositivo per la preparazione di una bevanda
DOP2009000222A (es) Formulaciones estables de anticuerpo
BR112014008551A2 (pt) conjunto de válvulas para uso com recipiente de líquido e frasco de medicamento
AR091961A1 (es) Inmunoconjugados y anticuerpos anti-etbr (receptor de endotelina b)
ECSP13013060A (es) Composiciones de nucleasa terapéuticas y métodos
MX2017005575A (es) Formulacion farmaceutica de anticuerpos anti-tnf alfa.
WO2013051878A3 (en) Antibody specifically binding to epitope in sema domain of c-met
BR112018008017A2 (pt) composição farmacêutica, método de preparação de composição farmacêutica líquida, kit farmacêutico, sistema de fornecimento de injeção
AR086823A1 (es) Formulaciones de anticuerpo anti-c-met, metodos
AR101455A1 (es) Molécula portadora
AR098996A1 (es) Formulación compuesta para la administración por vía oral que comprende ezetimiba y rosuvastatina
BR112016026811A2 (pt) formulação de anticorpo
BR112016013509A2 (pt) “sistema para a administração de inoculantes microbianos e materiais e métodos relacionados”.
BR112013009164A2 (pt) capsídeo de norovírus e proteína vp6 de rotavírus para uso como vacina combinada.
BR112015025748A2 (pt) construção de dna para imunomodulação, composição farmacêutica, vacina, e uso de uma construção de dna
BR112017000515A2 (pt) formulação de vacina contra rotavírus termoestável seca por liofilização e processo para preparação da mesma
CL2015001772A1 (es) Composición farmacéutica para el tratamiento de dolor cabeza, y método de preparación de la misma.
BR112013029417A2 (pt) composições de vacina de matriz proteica incluindo policátions
UY34567A (es) Método y sistema para transcodificar contenido en modo remoto
WO2014179184A8 (en) Compositions for inducing immune tolerance to coagulation factor proteins
AR075873A1 (es) Reconstitucion in situ de una vacuna para la administracion a un grupo de animales predeterminado
BR112018014123A2 (pt) formulação farmacêutica aquosa estável.
BR112016026239A8 (pt) bebida láctea, processo para a preparação e seu uso
AR102441A1 (es) Concentrado alimenticio

Legal Events

Date Code Title Description
FB Suspension of granting procedure